Skip to main content

Advertisement

SpringerLink
Log in

Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Whether hepatic arterial infusion (HAI) of oxaliplatin influences the rates of complete pathologic response (CPR) and severe oxaliplatin-related lesions (SOxL) in patients with colorectal liver metastases (CRLM) is unknown. This study aimed to compare the incidence of CPR and SOxL between systemic (intravenous, IV) and HAI administration.

Methods

All patients with initially unresectable CRLM who had undergone hepatic resection in two expert centers between 2004 and 2010 after at least 6 cycles of oxaliplatin-based chemotherapy administered either via HAI (n = 18) or IV (n = 50) were included. The presence of CPR and SOxL were evaluated by two pathologists. A 1:2 case match using a propensity score was used.

Results

A CPR was observed significantly more often after HAI (33 vs. 10 %, P = 0.03). However, SOxL had occurred more frequently in patients in the HAI group versus the IV group, 66 and 20 %, respectively (P < 0.001). On a well-balanced cohort, HAI was associated with higher chance of CPR (odds ratio 9.33, 95 % confidence interval 1.59–54.7) but also higher risk of SOxL (odds ratio 13.7, 95 % confidence interval 3.08–61.3). A CPR markedly enhanced overall survival (OS) and disease-free survival (median OS of 114 vs. 42 months, P = 0.02; median disease-free survival of 51 vs. 12 months, P = 0.002). Patients with SOxL did not experience different outcome (median OS of 42 vs. 50 months, respectively; P = 0.92)

Conclusions

HAI of oxaliplatin increases the likelihood of a CPR at the cost of a higher incidence of SOxL in patients with initially unresectable CRLM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.

    Article  PubMed  Google Scholar 

  3. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009;3:CD007823.

  4. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465–71.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005;23:4881–7.

    Article  CAS  PubMed  Google Scholar 

  6. Goere D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686–91.

    Article  PubMed  Google Scholar 

  7. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635–41.

    Article  PubMed  Google Scholar 

  8. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344–51.

    Article  PubMed  Google Scholar 

  9. Guthoff I, Lotspeich E, Fester C, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23(6D):5203–8.

    CAS  PubMed  Google Scholar 

  10. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–9.

    Article  PubMed  Google Scholar 

  11. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.

    Article  CAS  PubMed  Google Scholar 

  12. Rubbia-Brandt L, Tauzin S, Brezault C, et al. Gene expression profiling provides insights into pathways of oxaliplatin-related sinusoidal obstruction syndrome in humans. Mol Cancer Ther. 2011;10:687–96.

    Article  CAS  PubMed  Google Scholar 

  13. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.

    Article  CAS  PubMed  Google Scholar 

  14. Wicherts DA, de Haas RJ, Sebagh M, et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol. 2011;18:659–69.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Vreuls CP, Van Den Broek MA, Winstanley A, et al. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 2012;61:314–8.

    Article  PubMed  Google Scholar 

  16. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:421–30.

    Article  PubMed  Google Scholar 

  17. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232:777–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Levi F, Boige V, Hebbar M, et al. Final results of first European phase II trial of intravenous cetuximab and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer after systemic treatment failure (OPTILIV, NCT00852228) [abstract 466]. J Clin Oncol. 2013;31(suppl 4).

  20. Deschamps F, Rao P, Teriitehau C, et al. Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol. 2010;21:1681–8.

    Article  PubMed  Google Scholar 

  21. Honore C, Goere D, Dumont F, Elias D. Catheter placement for intra-arterial hepatic chemotherapy. J Visc Surg. 2012;149:389–94.

    Article  CAS  PubMed  Google Scholar 

  22. Malka DEP, Caramella C, Boucher E, et al. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): a multicenter phase II study. J Clin Oncol. 2010;28(15 suppl):3558.

    Google Scholar 

  23. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–75.

    Article  CAS  PubMed  Google Scholar 

  24. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.

    Article  CAS  PubMed  Google Scholar 

  25. Imamura H, Sano K, Sugawara Y, Kokudo N, Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg. 2005;12:16–22.

    Article  PubMed  Google Scholar 

  26. Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454–60.

    Article  PubMed  Google Scholar 

  27. Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg. 1995;180:213–9.

    CAS  PubMed  Google Scholar 

  28. Bismuth H. [Anatomy of the liver and hepatectomy techniques]. Ann Chir. 1998;52:61–3.

    CAS  PubMed  Google Scholar 

  29. Balzan S, Belghiti J, Farges O, et al. The “50–50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg. 2005;242:824–8.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Kemeny NE. The re-birth of hepatic arterial infusion for colorectal liver metastases. J Gastrointest Oncol. 2013;4:118–20.

    PubMed Central  PubMed  Google Scholar 

  31. Vigano L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731–40.

    Article  PubMed  Google Scholar 

  32. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006;24:4983–90.

    Article  CAS  PubMed  Google Scholar 

  33. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–24.

    Article  PubMed  Google Scholar 

  34. Narita M, Oussoultzoglou E, Chenard MP, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19:2230–7.

    Article  PubMed  Google Scholar 

  35. Makowiec F, Mohrle S, Neeff H, et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg. 2011;15:153–64.

    Article  PubMed  Google Scholar 

  36. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol. 2010;34:784–91.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors would like to thank Dr. David Malka, who provided the clinical data from the CHOICE study, and Lorna Saint Ange for editing.

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Centre Hépato-biliaire, Paul Brousse Hospital, Villejuif Cedex, France

    Marc Antoine Allard MD, Eric Vibert MD, PhD, René Adam MD, PhD & Antonio Sa Cunha MD

  2. Department of Pathology, Paul Brousse Hospital, Villejuif Cedex, France

    Mylène Sebagh MD

  3. Department of Molecular Biology, Paul Brousse Hospital, Villejuif Cedex, France

    Antoinette Lemoine MD, PhD

  4. Department of Surgical Oncology, Gustave Roussy, Villejuif Cedex, France

    Gaëlle Baillie MD, François Faitot MD, Matthieu Faron MD, Fabrizio Vitadello MD, Dominique Elias MD, PhD & Diane Goéré MD, PhD

  5. Department of Medical Oncology, Gustave Roussy, Villejuif Cedex, France

    Valérie Boige MD, PhD

  6. Department of Pathology, Gustave Roussy, Villejuif Cedex, France

    Peggy Dartigues MD

  7. Unité INSERM 776, Hôpital Paul Brousse, Villejuif Cedex, France

    René Adam MD, PhD & Antonio Sa Cunha MD

  8. Unité INSERM 1004, Hôpital Paul Brousse, Villejuif Cedex, France

    Marc Antoine Allard MD & Antoinette Lemoine MD, PhD

  9. Unité INSERM 785, Hôpital Paul Brousse, Villejuif Cedex, France

    Mylène Sebagh MD & Eric Vibert MD, PhD

Authors
  1. Marc Antoine Allard MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mylène Sebagh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaëlle Baillie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antoinette Lemoine MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peggy Dartigues MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. François Faitot MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthieu Faron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Valérie Boige MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fabrizio Vitadello MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eric Vibert MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dominique Elias MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. René Adam MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Diane Goéré MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Antonio Sa Cunha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Sa Cunha MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allard, M.A., Sebagh, M., Baillie, G. et al. Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases. Ann Surg Oncol 22, 1925–1932 (2015). https://doi.org/10.1245/s10434-014-4272-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4272-7

Keywords

Search

Navigation